Skip to main content

Table 6 OS according to baseline serum levels and CEA, CYFRA and NSE reduction ≥ 20%

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

  Mean OS (95% CI)a (months) p-value
Baseline CEA
< 5 12.2 (8.1–16.0) 0.035
≥ 5 5.6 (2.9–8.2)
Baseline CYFRA21-1
< 3.3 13.2 (11.0–14.3) 0.005
≥ 3.3 5.6 (3.4–7.7)
Baseline NSE
< 13.4 10.0 (6.2–13.7) 0.028
≥ 13.4 2.2 (0.2–5.0)
CEA reduction ≥ 20% a
No 9.9 (8.5–11.3) 0.026
Yes 15.0 (12.7–17.3)
CYFRA21-1 reduction ≥ 20% a
No 10.0 (8.4–11.6) 0.019
Yes 14.6 (12.4–16.8)
NSE reduction ≥ 20% a
No 11.6 (9.9–13.4) 0.950
Yes 12.4 (9.8–15.0)
  1. aMedian survival not reached